SAREPTA THERAPEUTICS INC (SRPT) Stock Price, Quote, News and Overview
NASDAQ:SRPT - Nasdaq - US8036071004 - Common Stock - Currency: USD
SRPT Quote, Performance and Key Statistics
SAREPTA THERAPEUTICS INC
NASDAQ:SRPT (2/4/2025, 8:09:07 PM)
After market: 114.08 0 (0%)114.08
+0.27 (+0.24%)
The current stock price of SRPT is 114.08 USD. In the past month the price decreased by -9.67%. In the past year, price decreased by -10.08%.
SRPT Latest News, Press Releases and Analysis
Sarepta Therapeutics' Duchenne Gene Therapy Shows Sustained Benefits And Disease Stabilization At Two Years
Sarepta's EMBARK study confirms Elevidys offers sustained Duchenne treatment benefits, including motor function improvement and minimal muscle pathology progression.
Biogen, Sarepta Quick Drug Approvals Show FDA Gaps, Report Says
Approvals for drugs from Biogen Inc. and Sarepta Therapeutics Inc. show flaws in the process US drug regulators use to speed approval for drugs to fill unmet needs, federal watchdogs said in a report.
Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2024 Net Product Revenue
Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference
/PRNewswire/ -- Hansa Biopharma AB, "Hansa" or the "Company" (Nasdaq Stockholm: HNSA), today announced that management will attend the 43rd Annual J.P. Morgan...
SRPT Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.77 | 335.67B | ||
| AMGN | AMGEN INC | 14.58 | 155.36B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 945.65 | 124.20B | ||
| GILD | GILEAD SCIENCES INC | 22.12 | 122.12B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.27 | 76.60B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.95B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.95B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.08B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.76B | ||
| NTRA | NATERA INC | N/A | 23.00B | ||
| BIIB | BIOGEN INC | 8.73 | 20.76B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.52 | 15.78B |
Related stock screener links
About SRPT
Company Profile
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 1,314 full-time employees. The firm is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. The company has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes approximately 40 programs at various stages of discovery, pre-clinical and clinical development.
Company Info
SAREPTA THERAPEUTICS INC
215 1st St Ste 415
Cambridge MASSACHUSETTS 02142 US
CEO: Douglas S. Ingram
Employees: 1314
Company Website: https://www.sarepta.com/
Investor Relations: https://investorrelations.sarepta.com
Phone: 16172744000
SRPT FAQ
What is the stock price of SRPT?
The current stock price of SRPT is 114.08 USD.
What is the symbol for SAREPTA THERAPEUTICS INC stock?
The exchange symbol of SAREPTA THERAPEUTICS INC is SRPT and it is listed on the Nasdaq exchange.
On which exchange is SRPT stock listed?
SRPT stock is listed on the Nasdaq exchange.
Is SRPT a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for SRPT, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of SRPT.
Does SRPT stock pay dividends?
SRPT does not pay a dividend.
What is the Price/Earnings (PE) ratio of SRPT?
The PE ratio for SRPT is 91.26. This is based on the reported non-GAAP earnings per share of 1.25 and the current share price of 114.08 USD.
What is the Short Interest ratio of SRPT stock?
The outstanding short interest for SRPT is 5.51% of its float.
SRPT Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to SRPT. When comparing the yearly performance of all stocks, SRPT is a bad performer in the overall market: 76.04% of all stocks are doing better.
SRPT Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to SRPT. Both the profitability and the financial health of SRPT get a neutral evaluation. Nothing too spectacular is happening here.
SRPT Financial Highlights
Over the last trailing twelve months SRPT reported a non-GAAP Earnings per Share(EPS) of 1.25. The EPS decreased by 115.96% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 7.43% | ||
| ROA | 3.38% | ||
| ROE | 9.98% | ||
| Debt/Equity | 0.93 |
SRPT Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to SRPT. The Buy consensus is the average rating of analysts ratings from 29 analysts.
For the next year, analysts expect an EPS growth of 143.28% and a revenue growth 51.52% for SRPT